Aventis Taxotere Approved For Breast Cancer; Lowers Relapse Chance 25.7%
Executive Summary
Aventis added an adjuvant node-positive breast cancer indication for Taxotere Aug. 18
You may also be interested in...
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Taxotere approved for prostate cancer
Aventis' Taxotere (docetaxel) adds indication for treatment of hormone refractory prostate cancer in combination with prednisone May 19. Revised 1labeling includes data from 335 patients showing median survival advantage of 2.4 months versus mitoxantrone (Amgen/OSI's Novantrone). Taxotere is first drug to show survival benefit in that population, FDA says. Aventis is also investigating Taxotere as first-line prostate cancer therapy...